Form 8-K - Current report:
SEC Accession No. 0001367644-25-000054
Filing Date
2025-03-10
Accepted
2025-03-10 16:47:34
Documents
15
Period of Report
2025-03-10
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20250310.htm   iXBRL 8-K 30133
2 EX-99.1 pressrelease_03102025.htm EX-99.1 12348
  Complete submission text file 0001367644-25-000054.txt   204002

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20250310.xsd EX-101.SCH 2101
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20250310_def.xml EX-101.DEF 15328
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20250310_lab.xml EX-101.LAB 27218
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20250310_pre.xml EX-101.PRE 16030
17 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20250310_htm.xml XML 2722
Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 25724470
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)